Mereo BioPharma Group PLC
MREO
Company Profile
Business description
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Contact
One Cavendish Place
4th Floor
LondonW1G 0QF
GBRT: +44 3330237300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.90 | 42.50 | 0.47% |
| CAC 40 | 8,151.38 | 0.74 | 0.01% |
| DAX 40 | 24,288.40 | 88.90 | 0.37% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,897.42 | 59.65 | 0.61% |
| HKSE | 25,759.28 | 68.75 | 0.27% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 50,503.92 | 996.71 | 2.01% |
| NZX 50 Index | 13,446.26 | 112.86 | 0.85% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,701.80 | 41.60 | 0.48% |
| SSE Composite Index | 3,913.65 | 23.21 | 0.60% |